The search is over, and the question is now whether the target justifies the price. D. Boral Acquisition Corp., a British Virgin Islands blank check company, signed a definitive merger agreement with Exascale Labs Inc. in the first quarter of 2026. The deal ended a search that began after the February 2026 closing of its initial public offering. Exascale is a Houston-based artificial intelligence infrastructure provider that operates an asset-light GPU compute platform, and the combined entity, to be renamed Exascale Labs Holdings Inc., values the target at an aggregate merger consideration of $500,000,000.
The investment question has changed character from the previous filing. The prior quarter's analysis was about whether the sponsor could source a target inside the 18-month window. The question now is whether Exascale justifies a $500 million equity valuation when the trust holds roughly $291.5 million of near-cash that public holders can redeem at any time before the deal vote. Revenue reached $10.6 million in the period through the spring of 2026. The market is pricing the equity at trust value, the same answer it gave to the search-stage shell, and that pricing says the optionality of the Exascale deal is worth approximately nothing over a Treasury instrument with the same maturity.
The falsifiable clock is the deal vote, which is subject to a hard deadline in the first quarter of next year. The sponsor holds a one-time three-month extension option that pushes the date into the spring. A named target with disclosed terms and a trust that can fund only the minimum cash condition after redemptions creates a specific set of observable outcomes. Either the deal closes with redemptions low enough to keep the combined entity solvent and listed, or the trust is returned to public holders and Exascale remains private. The third quarter filing, due in the fall, is the first data point that tests whether the trust balance has eroded or held steady ahead of the vote.